Business Context and Reporting Period
This Form 8-K Current Report was filed by Alnylam Pharmaceuticals, Inc. on September 8, 2021, regarding an event that occurred on September 6, 2021. The filing addresses the departure of a named executive officer and the associated compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It is a current report focused on corporate governance and executive compensation rather than financial performance.
Material Changes
The primary material change reported is the retirement of Laurie B. Keating, Executive Vice President, Chief Legal Officer, and Secretary, effective September 10, 2021, following seven years of service. In connection with her departure, the Company entered into a Letter Agreement on September 6, 2021.
Guidance, Outlook, and Management Commentary
Ms. Keating will transition to a consultant role for an 18-month period, providing up to 10 hours of service per month. The compensatory package includes:
- Cash compensation equal to her current base rate of pay for 12 months.
- A pro-rata cash bonus for 2021 based on actual performance, payable under the Annual Incentive Program.
- A lump sum equal to the Company's contribution toward her health coverage premium for 12 months.
- Continued vesting and exercisability of equity awards during the consulting period.
The agreement includes a release of claims. The full text of the Letter Agreement is intended to be filed as an exhibit to the Quarterly Report on Form 10-Q for the quarter ending September 30, 2021.
Investor Verification Checklist
- Verify the appointment of a successor to the roles of Executive Vice President, Chief Legal Officer, and Secretary.
- Review the full Letter Agreement when filed as an exhibit to the Q3 2021 Form 10-Q for complete terms and conditions.
- Monitor future filings for any additional executive departures or changes in legal leadership.